Skip to main content
Premium Trial:

Request an Annual Quote

John Gilligan, James Oblinger, Terri Lomax, Jim Chrisman, John Dunning, Leslie Leinwand, Terry Opgenorth, John Poate, Rae Reynolds, Jim Skrine, Rulon Stacey, Dan Stinchcomb


John Gilligan on June 1 will leave his current position as vice chancellor for research and graduate studies at North Carolina State University in order to return to NC State’s College of Engineering as a faculty member and special advisor to the dean.
NC State’s vice chancellor for research and graduate studies is responsible for state, federal, industry, and foundation-sponsored programs; university regulatory compliance, sponsored program support, university project development, technology transfer and commercialization, and NC State's graduate school.
“John's work as vice chancellor has helped NC State continue to build its patent portfolio and continue its strong support of start-up companies and economic development in general,” NC State Chancellor James Oblinger said in a statement.
Oblinger said the university would begin a national search for Gilligan’s replacement “soon.”
Terri Lomax, dean of the graduate school, has been named interim vice chancellor.
Gilligan joined NC State as a nuclear engineering faculty member in 1983 and has served as vice chancellor since 2002. During his tenure as vice chancellor, the university’s patent holdings grew to more than 600, while the number of spin-off companies grew to 68, NC State said.

The Colorado BioScience Association has elected nine new members to its 40-member board of directors. Newly elected CBSA board members include:
  • Jim Chrisman, senior vice president of Forest City;
  • John Dunning, president and CEO of Clarimedix;
  • Leslie Leinwand, director of the Colorado Initiative in Molecular Biotechnology and a professor in the department of biology at the University of Colorado;
  • Terry Opgenorth, chief operating officer of MicroRx and NeoTREX;
  • John Poate, vice president for research and technology transfer at the Colorado School of Mines;
  • Rae Reynolds, president of the Kaleidoscope Group;
  • Jim Skrine, executive director of quality at Amgen;
  • Rulon Stacey, president and CEO of Poudre Valley Health System; and
  • Dan Stinchcomb, CEO and co-founder of Inviragen.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.